• Product name
    Anti-Tau antibody [E178]
    See all Tau primary antibodies
  • Description
    Rabbit monoclonal [E178] to Tau
  • Host species
  • Specificity

    The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat.

  • Tested applications
    Suitable for: IHC-P, WB, IPmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Mouse, Rat, Human
    Predicted to work with: Cow
  • Immunogen

    Synthetic peptide within Human Tau aa 700 to the C-terminus. The exact sequence is proprietary.
    Database link: P10636

  • Positive control
    • WB: SH-SY5Y cell lysate, Mouse brain, Human brain and Rat hippocampus tissue lysates. IP: Human fetal brain lysates. IHC-P: Human brain and cerebrum tissue.
  • General notes

    A trial size is available to purchase for this antibody.


    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab32057 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/4000. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

See IHC antigen retrieval protocols.

The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat.

For unpurified use at 1/500 - 1/1000

WB 1/1000. Predicted molecular weight: 79 kDa.

For unpurified use at 1/5000

IP 1/20.

For unpurified use at 1/100

  • Application notes
    Is unsuitable for Flow Cyt.
  • Target

    • Function
      Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
    • Tissue specificity
      Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
    • Involvement in disease
      Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
      Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
      Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
      Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
      Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
    • Sequence similarities
      Contains 4 Tau/MAP repeats.
    • Developmental stage
      Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
    • Domain
      The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
    • Post-translational
      Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
      Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
      Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
    • Cellular localization
      Cytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
    • Information by UniProt
    • Database links
    • Form
      There are 9 isoforms produced by alternative splicing.
    • Alternative names
      • AI413597 antibody
      • AW045860 antibody
      • DDPAC antibody
      • FLJ31424 antibody
      • FTDP 17 antibody
      • G protein beta1/gamma2 subunit interacting factor 1 antibody
      • MAPT antibody
      • MAPTL antibody
      • MGC134287 antibody
      • MGC138549 antibody
      • MGC156663 antibody
      • Microtubule associated protein tau antibody
      • Microtubule associated protein tau isoform 4 antibody
      • Microtubule-associated protein tau antibody
      • MSTD antibody
      • Mtapt antibody
      • MTBT1 antibody
      • MTBT2 antibody
      • Neurofibrillary tangle protein antibody
      • Paired helical filament tau antibody
      • Paired helical filament-tau antibody
      • PHF tau antibody
      • PHF-tau antibody
      • PPND antibody
      • PPP1R103 antibody
      • Protein phosphatase 1, regulatory subunit 103 antibody
      • pTau antibody
      • RNPTAU antibody
      • TAU antibody
      • TAU_HUMAN antibody
      • Tauopathy and respiratory failure, included antibody
      see all


    • Anti-Tau antibody [E178] (ab32057) at 1/100 dilution (Purified) + Human brain lysates at 15 µg

      Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

      Predicted band size: 79 kDa
      Observed band size: 55-74 kDa
      why is the actual band size different from the predicted?

      The observed molecular weights are consistent with what have been described in literature PMID: 9276470

    • Anti-Tau antibody [E178] (ab32057) at 1/5000 dilution (Purified) + Mouse brain lysates at 15 µg

      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size: 79 kDa
      Observed band size: 55-74 kDa why is the actual band size different from the predicted?

      The observed molecular weights are consistent with what have been described in literature PMID: 9276470

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human cerebrum tissue sections labeling Tau with purified ab32057 at 1/4000 dilution (0.03 µg/ml). Perform heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
    • All lanes : Anti-Tau antibody [E178] (ab32057) at 1/1000 dilution

      Lane 1 : Untreated SH-SY5Y cell
      Lane 2 : SH-SY5Y cell
      lysate SH SY5Y cell lysate treated with Oka/CalA. Cells are serum-starved overnight, and then treated with 1nM calyculin A and 500nM Okadaic acid for 2 hours at 37°C.

      Predicted band size: 79 kDa

    • ab32057 (purified) at 1/20 dilution (0.5ug) immunoprecipitating Tau in Human fetal brain lysates.
      Lane 1: Human fetal brain lysates 10ug
      Lane 2 (+): ab32057 & Human fetal brain lysates
      Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab32057 in Human fetal brain lysates
      For western blotting, VeriBlot for IP Detection Reagent (HRP)�(ab131366) was used at 1/1000 dilution.
      Blocking and diluting buffer: 5% NFDM/TBST.
    • Immunohistochemistical detection of Tau antibody [E178] (ab32057) on formaldehyde fixed paraffin-embedded rat tongue sectionsAntigen retrieval step: Heat mediated. Buffer Used: Citric acid pH6. Permeabilization: None. Primary antibody incubated at 1/1000 for 2 hours @ 21°C in TBS/BSA/azide. Secondary antibody: anti Rabbit IgG Conjugated to Biotin (1/200). A strong pattern of immunostaining which appears to be mostly localised to nerve fibres and their cell bodies (Islet of Langerhans cells are also positive). In submitted image of central area of tongue coloured arrowheads indicate features: red for nerves cut in cross-section (T/S), each brown dot representing a single axon green for what appears to me to be small nerve fibres wrapping around a partial muscle fibre black for a Ganglion containing seven positive nerve cell bodies. Surrounding these are collagen fibres (C), adipocytes (A) and skeletal/striated muscle fibres in L/S ( M-

      See Abreview

    • Immunohistochemistical detection of Tau antibody [E178] (ab32057) on formaldehyde-fixed paraffin-embedded human salivary gland sections. Antigen retrieval step: Heat mediated.  Buffer Used: Citric acid pH6. Permeabilization: No.  Blocking step: 1% BSA for 10 mins @ 21°C. ab32057 incubated at 1/1000 for 2 hours @  21°C in TBS/BSA/azide. Secondary antibody:  anti rabbit IgG conjugated to Biotin (1/200). NB: An interesting pattern of positivity that seems to be supported by the Human Protein Atlas. Coloured arrowheads in the submitted image indicate features: red for positive serous glands, blue for positive intra-lobular collecting ducts, black for negative mucous glands (there is a serous demilune around this acinus), yellow for intralobular collecting ducts, green for nerve tracks in the interlobular areas, blue for positive interlobular collecting ducts. There appears to be a population of positive nuclei but this may b

    • Ab32057, at a dilution of 1/500, staining Tau in paraffin embedded human brain sections by Immunohistochemistry.


    This product has been referenced in:
    • Zhang L  et al. miR-125b promotes tau phosphorylation by targeting the neural cell adhesion molecule in neuropathological progression. Neurobiol Aging 73:41-49 (2019). Read more (PubMed: 30316051) »
    • Ham TR  et al. Automated Gait Analysis Detects Improvements after Intracellular s Peptide Administration in a Rat Hemisection Model of Spinal Cord Injury. Ann Biomed Eng 47:744-753 (2019). Read more (PubMed: 30627839) »
    See all 25 Publications for this product

    Customer reviews and Q&As

    1-4 of 4 Abreviews or Q&A


    Thank you for contacting Abcam regarding these antibodies.

    I am sorry that your customer is experiencing difficulties with these antibodies in WB. Based on the protocol information and information we have about the protein, there does not seem to be a good explanation for why you are detecting a band at the incorrect molecular weigt, and importantly, at the same molecular weight.

    I noticed that the customer has not performed a no primary control. Is the customer sure that the secondary antibody is working well and not the cause of background? I would advise performing this important control and considering testing another secondary antibody as well.

    If the secondary antibody does not appear to be the cause of the problem, I am happy to offer a replacement or credit.

    I look forward to your reply so that I may assist you further. Please do not hesitate to contact me if you have any additional questions.

    Read More
    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Rat Tissue sections (Tongue)
    Antigen retrieval step
    Heat mediated - Buffer/Enzyme Used: Citric acid pH6
    Blocking step
    (agent) for 10 minute(s) · Concentration: 1% · Temperature: 21°C

    Mr. Carl Hobbs

    Verified customer

    Submitted Nov 02 2010

    Western blot
    Human Cell lysate - whole cell (SH-SY5Y cell line)
    Loading amount
    12 µg
    SH-SY5Y cell line
    Gel Running Conditions
    Reduced Denaturing (8)
    Blocking step
    BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: RT°C

    Dr. Víctor Campa

    Verified customer

    Submitted Mar 09 2010


    Thank you for taking the time to call me yesterday. Ab30663 recognises the isoform of Tau around the 48KDa mark. My colleague has spoken with a friend who works in this field. It is well known within the field that blotting against the non phospho form of Tau will give multiple bands (ranging from 45-65 KDa) this represents multiple isoforms of the target. The dominant isoform (even the phospho forms) will vary depending upon the species and the stage of development (which is why the other Ab to the same target detects a different sized band). There is a good review on the dephosphorylation of Tau written by Hanger et al about ten years ago that would be of use to you in this field. I think the Pub Med ID is: 11447841; however if you search Hanger DP a whole list of suitable papers can be found. I hope that this helps. Should you have any further questions then please do not hesitate to get back in touch with me.

    Read More

    For licensing inquiries, please contact partnerships@abcam.com

    Sign up